Introduction
In alignment with the FDA Modernization Act 2.0 and the FDA’s 2025 Strategic Roadmap for Reducing Animal Testing regulatory agencies are actively encouraging the adoption of scientifically validated New Approach Methodologies (NAMs) in place of traditional animal models.
Against this backdrop, the pharmaceutical industry is navigating a critical transition: modernizing immunogenicity safety profile strategies for biosimilars by eliminating reliance on animal studies and improving human predictivity. By leveraging human Microphysiological Systems (MPS) integrated with AI-driven in silico modeling, developers are achieving dramatic reductions in testing timelines while generating 100 percent human-relevant immune data.
This transformation illustrates how AI in drug development, human-relevant NAMs, and mechanistic immune modeling are reshaping biosimilar safety profiling from a compliance burden into a strategic advantage.
The Translational Gap in Immunogenicity Assessment
Immunogenicity remains one of the most critical determinants of biologic and biosimilar safety. Anti-Drug Antibody (ADA) formation can compromise efficacy, alter pharmacokinetics, and trigger adverse immune reactions. Traditionally, companies have relied on animal models to predict these outcomes — but this strategy presents a structural limitation.
Animal immune systems diverge significantly from human immunobiology. Even non-human primates often fail to replicate human HLA-restricted antigen presentation and immune memory formation. As a result, animal-based immunogenicity studies frequently demonstrate poor translational value, creating a “Translational Gap” between preclinical prediction and clinical outcome.
This gap becomes particularly problematic for biosimilars, where subtle structural differences can alter epitope presentation and immune recognition. Regulatory authorities, including the FDA and EMA, now recognize this limitation and are explicitly advocating for mechanistically validated NAMs that are human-relevant by design. The shift is legislative, scientific, and strategic.
Regulatory Shift: From Animal Models to Human-Relevant NAMs
For nearly a century, animal testing has been embedded into regulatory toxicology and immunogenicity workflows. Yet the pharmaceutical industry is now navigating its most significant regulatory inflection point in decades.
The passage of the FDA Modernization Act 2.0 formally removed the blanket requirement for animal testing in certain drug approval contexts, enabling validated alternatives such as organ-on-chip systems and advanced in vitro platforms. This legislative change was not symbolic, it fundamentally altered the compliance landscape.
The FDA’s 2025 Strategic Roadmap for Reducing Animal Testing further operationalizes this shift, outlining a structured plan to accelerate the adoption of NAMs. The message from regulators has evolved from allowing alternatives to expecting scientifically robust, human-relevant methods wherever feasible. In this environment, continued reliance on animal models increasingly represents not just scientific conservatism but regulatory risk.
Immunogenicity in Biosimilars: Why Predictive Precision Matters
Immunogenicity assessment is not a box-ticking exercise, it is central to biologic safety. The formation of Anti-Drug Antibodies (ADAs) can:
- Neutralize therapeutic efficacy
- Alter pharmacokinetics and pharmacodynamics
- Trigger hypersensitivity reactions
- Compromise long-term treatment outcomes
For biosimilars, the challenge is amplified. Developers must demonstrate comparability to a reference product, ensuring that even subtle molecular differences do not alter immunogenicity profiles. Relying on animal models often leads to inconsistent immune response data, limited translatability, high costs, and extended timelines.
Case Study Spotlight: Assessing Immunogenicity through Non-Animal NAMs
Recognizing the regulatory and scientific shift early, a leading Indian biopharmaceutical company with a portfolio of over eight globally distributed biologics sought to future-proof its safety profiling.
- The Problem: The company’s reliance on animal models was creating a cycle of inefficiency. Poor translational value, inconsistent data, and the high cost and time of in vivo studies were hindering drug development. They urgently needed a scalable, AI-driven alternative to deliver mechanistically validated immune insights.
- The Solution: The company deployed Quantiphi’s DART (Digital Animal Replacement Technology) platform. DART combined ethically sourced, biobank-derived human Microphysiological Systems (via Transcell) with Quantiphi’s AI-powered computer vision and deep learning models. This benchtop-deployable system enabled rapid, parallel in vitro testing and automated analysis.
- The Impact: The transformation was immediate and measurable:
- 70 percent reduction in immunogenicity testing time.
- Fully human-relevant immune system modeling.
- Complete elimination of costly, time-consuming animal studies.
- Early detection of preliminary immune indicators and ADA signals.
- Full in-house scalability, giving the client total control over their data for both preclinical and clinical phases.
“With regulatory agencies advocating for alternative methods to animal testing, innovative solutions—such as Transcell’s human Microphysiological Systems combined with Quantiphi’s AI and ML-driven in-silico modeling—offer promising avenues to create more predictive and effective scientific tools.” — Client Testimonial
Read more
The DART Platform: Bridging the Translational Gap
To achieve the results seen in the case study, Quantiphi’s DART platform integrates structural, phenotypic, and biochemical signals within a unified framework, moving beyond traditional assays that rely solely on endpoint measurements.
Technical Entity Mapping: MAPPs and ADA Detection
Modern regulatory science prioritizes technical specificity; mechanistic detail matters.
- MHC-Associated Peptide Proteomics (MAPPs): MAPPs assays identify naturally presented HLA class II-associated peptides on antigen-presenting cells, providing insight into which epitopes are actually processed and presented to T cells rather than merely predicted to bind. DART’s immune modeling incorporates comparable mechanistic principles within a human hematopoietic milieu, strengthening the prediction of T cell-dependent immunogenicity.
- Early ADA Signal Detection: Instead of relying on late-stage clinical signals, AI-enabled analysis captures early antigenicity indicators. This transforms immunogenicity assessment from reactive observation to proactive risk identification.
How the AI Engine Works: Deep Learning Segmentation in Action
Regulators increasingly value transparency in methodology. DART’s AI-driven workflow follows a structured, reproducible process:
- High-resolution micrograph acquisition of immune cultures.
- Deep learning-based segmentation of immune cell populations.
- Quantification of morphological and clustering changes.
- Detection of phenotypic activation markers.
- Correlation with biochemical assays in parallel.
- Automated reporting aligned with regulatory documentation standards.
By replacing subjective manual analysis with deep learning segmentation, phenotypic shifts linked to antigenicity are captured early, providing mechanistic validation that strengthens submission packages.
While no in vitro system perfectly replicates the complexity of systemic human immunity, eliminating interspecies extrapolation significantly improves biological relevance compared to animal proxies.
Comparative Utility: Animal Models vs. Human Microphysiological Systems
A structured comparison clarifies the strategic implications of adopting NAMs:
| Dimension | Non-Human Primate Models | DART Human MPS with AI |
|---|---|---|
| Species Relevance | Partial; interspecies divergence | Directly human-derived immune modeling |
| Translational Predictivity | Often inconsistent | Direct modeling of human immune pathways |
| Time to Data | Extended in vivo study timelines | 70 percent reduction in testing time |
| Cost Structure | High operational and ethical cost | Significant cost elimination from animal studies |
| Scalability | Limited; often outsourced | Benchtop deployable and in-house scalable |
| Mechanistic Resolution | Limited phenotypic granularity | Bypasses species-mismatched immune noise and phenotypic limits by AI-powered mapping of human molecular pathways directly |
The Broader Strategic Implication for Biosimilar Developers
The immunogenicity landscape is evolving across three converging axes: legislative change (FDA Modernization Act 2.0), strategic enforcement (FDA 2025 Roadmap), and technological capability (AI and MPS).
Companies that continue relying solely on animal models risk delayed approvals, late-stage clinical failures due to poor translation, and increased scrutiny during regulatory review. Conversely, early adopters of validated human-relevant NAMs gain accelerated timelines, mechanistically defensible submissions, enhanced partner confidence, and cost-effective safety profiling.
Conclusion: Redesigning Immunogenicity for the AI Era
The future of immunogenicity testing lies at the intersection of human biology and artificial intelligence. By integrating hematopoietic immune modeling, MAPPs-aligned antigen presentation insights, ADA precursor detection, and deep learning segmentation, the DART platform redefines biosimilar safety profiling.
Immunogenicity assessment is no longer about approximating human biology through animal proxies. It is about modeling human biology directly, with computational precision and regulatory transparency. For biopharmaceutical leaders preparing the next generation of biosimilars, the strategic question is no longer whether NAMs will replace animal testing — it is how rapidly they can be validated, standardized, and embedded into core development pipelines.
Quantiphi’s DART platform gives biosimilar developers a validated starting point for that transition, combining human-relevant biology with AI-driven precision to de-risk submissions and accelerate time to approval.
Ready to Modernize Your Immunogenicity Framework?
Frequently Asked Questions
The FDA Modernization Act 2.0, enacted in 2022, removed the blanket requirement for animal testing in certain drug approval pathways. It allows sponsors to use scientifically validated alternatives such as in vitro assays, organ-on-chip systems, computational models, and other NAMs. For immunogenicity testing, developers can now justify human-relevant, mechanistically validated models instead of relying solely on animal studies.
NAMs are non-animal testing strategies that generate safety and efficacy data using human-relevant systems. They include Microphysiological Systems (organ-on-chip platforms), advanced in vitro immune assays, MAPPs assays, and AI-driven computational modeling. They aim to improve translational predictivity by modeling human biology directly.
Animal models fail to reliably predict human immunogenicity due to key biological and physiological divergences, a disconnect known as the “translational gap”:
- Interspecies Divergence: Species differences in HLA-restricted antigen presentation prevent animals (even non-human primates) from replicating human immune recognition.
- Immune History: Lab animals raised in sterile environments have naive immune systems, whereas humans have decades of accumulated immune memory that alter baseline reactivity.
- Xenogenic Reactions: Human biotherapeutics act as foreign proteins in animals, triggering anti-drug antibodies that reflect interspecies rejection rather than true clinical risk in humans.
MHC-Associated Peptide Proteomics (MAPPs) identifies peptides that are naturally processed and presented on HLA class II molecules by antigen-presenting cells. Unlike theoretical binding prediction models, MAPPs capture epitopes actually presented to T cells, providing stronger mechanistic insight into potential immunogenicity.
AI automates image segmentation of immune cell cultures, quantifies phenotypic activation markers, and detects early antigenicity patterns. Deep learning models can identify subtle immune activation signals that may not be apparent through manual analysis, significantly reducing subjectivity in data interpretation.
Microphysiological Systems are advanced in vitro platforms that model human tissues or immune environments using human-derived cells. Applied to immunogenicity, hematopoietic immune modeling allows researchers to study antigen presentation, T cell activation, and early ADA precursor formation in a human-relevant context.
Not universally, at least not yet. Full replacement depends on validation, reproducibility, and scientific justification. However, in many contexts, NAMs can significantly reduce or eliminate certain animal studies, particularly where human-relevant systems provide superior mechanistic insight.
They offer improved translational predictivity, earlier detection of immunogenicity risk, reduced development timelines, lower operational costs, and mechanistically defensible regulatory submissions.
